EntryPoint Capital’s Protara Therapeutics TARA Stock Holding History

EntryPoint Capital’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.7K	Buy	+19,286	New	+$91.7K	0.02%	755

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

EntryPoint Capital's TARA Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Protara Therapeutics (TARA) in Q2 2026: 19,286 shares worth $73.7K. The stake represents 0.02% of the portfolio and ranks #755 among its holdings.

120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

EntryPoint Capital held 19,286 shares of Protara Therapeutics worth $73.7K as of Q2 2026.
Protara Therapeutics was a new EntryPoint Capital position in Q2 2026.
Protara Therapeutics made up 0.02% of EntryPoint Capital's portfolio in Q2 2026, its #755 holding.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.